Method for treating breast cancer with prolactin receptor agonists
AssigneeOrbis Health Solutions LLC
InventorsWen Yuan Chen, Eric H. Lee
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods useful for the treatment of cancer, such as breast cancer. In some embodiments, the methods and compositions include human prolactin, or human prolactin in conjunction with a cytotoxic agent. In other embodiments, the methods and compositions include one or more of human prolactin, growth hormone and placental lactogen, or one or more of human prolactin, growth hormone and placental lactogen in conjunction with a cytotoxic agent. In some embodiments, the cytotoxic agent comprises a chemotherapeutic agent.
Claims4
A method of reducing the number of breast cancer cells in a patient comprising:
- administering a therapeutically effective amount of a human growth hormone to the patient and concurrently or sequentially administering a therapeutically effective amount of a chemotherapeutic agent, wherein the human growth hormone is a prolactin receptor agonist.
A method for treating a patient having breast cancer, comprising administering a therapeutically effective amount of a human growth hormone to the patient and concurrently or sequentially administering a therapeutically effective amount of a chemotherapeutic agent, wherein the human growth hormone is a prolactin receptor agonist.
A method of reducing the risk of recurrence of breast cancer in a patient diagnosed with the breast cancer, comprising administering a therapeutically effective amount of a human growth hormone to the patient and concurrently or sequentially administering a therapeutically effective amount of a chemotherapeutic agent, wherein the human growth hormone is a prolactin receptor agonist.
A method of increasing the time to relapse of a breast cancer in a patient diagnosed with the breast cancer, comprising administering to the patient a therapeutically effective amount of a human growth hormone and concurrently or sequentially administering a therapeutically effective amount of a chemotherapeutic agent, wherein the human growth hormone is a prolactin receptor agonist.
Dependencies are inferred from the claim text.